South Jordan-based Health Catalyst Inc., a leading provider of data and analytics technology and services to healthcare organizations, has announced that it has entered into an agreement to acquire Twistle Inc., an Albuquerque, New Mexico-based healthcare patient engagement technology company.
“We anticipate that Twistle’s leading clinical workflow and patient engagement platform, paired with the Health Catalyst population health offering, will enable a comprehensive go-to-market solution to address the population health needs of healthcare organizations, as well as life science organizations, around the globe,” Health Catalyst said in a statement. “Our cloud-based data platform DOS will enhance Twistle’s automation by enabling richer data-driven patient interaction. The Twistle technology also enables Health Catalyst’s clinical, quality and life sciences solutions, through established clinical pathways and patient communication channels.”
“Twistle is a leading healthcare technology company committed to developing software that healthcare organizations and life science companies need to keep patients engaged in their healthcare,” said Dan Burton, CEO of Health Catalyst. “Their efforts to improve patient outcomes and reduce the cost of care are deeply aligned with our mission to be the catalyst for massive, measurable, data-informed improvements. We’re excited to welcome the Twistle team to Health Catalyst and look forward to working together to enable healthcare organizations to achieve the promise of population health.”
“The synergy between our cultures, values and solutions will have a tremendous impact on the health and wellness of patients,” said Kulmeet Singh, founder and CEO of Twistle. “Health Catalyst’s patient insights can trigger personalized outreach and the patient’s unique profile will allow Twistle’s communication pathways to adapt to their preferences and attributes in unprecedented ways. We are excited about the prospects of our joint solutions proactively engaging at-risk populations, advancing health equity, and improving patient activation in their care.”
Financial details of the acquisition were not disclosed. The parties expect the transaction, which is subject to customary closing conditions, to close early in the third quarter 2021.
